Psoriasis and Psoriatic Arthritis Management: The Dermatologist's Perspective

Psoriasis and Psoriatic Arthritis Management: The Dermatologist's Perspective (One Hour Educational Activity)

Presented by Paul S. Yamauchi, MD, PhD and Kim A. Papp, MD, PhD, FRCPC

This is from a Live Webinar that took place on June 10, 2020 at 7:00 pm GMT+3 (Beirut time)

CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare — USA

Release Date: July 14, 2020 | Expiration Date: July 14, 2021

Activity Description/Practice Gap

With a variety of biologic therapies now available for treating psoriasis and psoriatic arthritis, examining the efficacy of these therapies on psoriatic disease severity can help with treatment selection and optimization. Selection of appropriate biologic therapy for moderate to severe psoriasis and psoriatic arthritis must factor in safety and adherence in addition to current efficacy. Successful treatment of psoriasis and psoriatic arthritis also requires proper monitoring and disease prevention for patients receiving biologic therapy. Monitoring of patients with psoriasis should also include looking for signs of arthritis. Psoriatic arthritis may develop in up to 30% of patients with psoriasis, yet its diagnosis is often missed. Dermatologists play a key role in identifying and managing patients with psoriatic arthritis. In this educational activity, Dr. Yamauchi will review the latest clinical evidence on the use of biologic therapies in the management of patients with psoriasis or psoriatic arthritis, and Dr. Papp will discuss how to identify and manage patients with psoriatic arthritis.

Goal

To improve dermatologist knowledge of current and emerging medications for psoriasis and psoriatic arthritis, appropriate monitoring and disease prevention for patients on biologics, and identification and management of patients with psoriatic arthritis.

Learning Objectives

After completing this activity, participants will be better able to:

· Examine efficacy of various biologics on psoriatic disease severity

· Select appropriate biologic therapies for moderate to severe psoriasis and psoriatic arthritis based on current efficacy, safety, and adherence

· Understand proper monitoring and disease prevention for patients on biologics

· Identify and manage psoriatic arthritis

Agenda (hour(s) : minute(s) : second(s))

00:00:00 - 00:32:56 Timestamp: Dr. Yamauchi Discusses the Initiation and Long-Term Management of Psoriasis and Psoriatic Arthritis with Biologic Agents - Choosing the Right Drug

00:32:57 - 01:00:29 Timestamp: Dr. Papp Converses Regarding Identifying and Managing Psoriatic Arthritis: What Dermatologists Need to Know

Faculty / Lecturers

How to Receive Credit

Participants wishing to earn CME credit must:

1. Watch the entire video.

2. Complete the evaluation form online by clicking here.

3. A certificate of credit will be automatically generated upon successful completion of the activity.

Please claim your credit by July 14, 2021.

Faculty Disclosures

Dr. Yamauchi reports the following relationships:

Consultant: AbbVie, Amgen, Janssen, Novartis, Lilly, Ortho-Dermatologics, Sun Pharma, UCB

Speakers Bureau: AbbVie, Amgen, Janssen, Novartis, Lilly, Ortho-Dermatologics, Sun Pharma, UCB

Contracted Research: AbbVie, Amgen, Janssen, Novartis, Lilly, Ortho-Dermatologics, Sun Pharma, UCB

Dr. Papp reports the following relationships:

Consultant: AbbVie, Akros, Amgen, Arcutis, Astellas, Bausch Health/Valeant, Baxalta, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CanFite Biopharma, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly, Evelo, Galapagos, Galderma, Genentech, Janssen, Kyowa Hakko Kirin, Leo Pharma, Meiji Seika Pharma, Merck Sharp & Dohme, Merck Serono, Mitsubishi Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis/Genzyme, Takeda, UBC

Speakers Bureau: AbbVie, Amgen, Astellas, Bausch Health/Valeant, Celgene, Eli Lilly, Galderma, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi-Aventis/Genzyme

Contracted Research: AbbVie, Akros, Amgen, Anacor, Arcutis, Astellas, Bausch Health/Valeant, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, CanFite Biopharma, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly, Evelo, Galapagos, Galderma, Genentech, Gilead, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Leo Pharma, Medimmune, Merck Sharp & Dohme, Merck Serono, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sun Pharma, Takeda, UBC

Honoraria: AbbVie, Akros, Amgen, Bausch Health/Valeant, Boehringer Ingelheim, Celgene, Coherus, Eli Lilly, Galderma, Janssen, Kyowa Hakko Kirin, Merck Sharp & Dohme, Merck Serono, Mitsubishi Pharma, Novartis, Pfizer, PRCL Research, Sanofi-Aventis/Genzyme, Takeda, UBC

Scientific Officer: Akros, Anacor, Arcutis, Kyowa Hakko Kirin

Steering Committees: AbbVie, Amgen, Bausch Health/Valeant, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Kyowa Hakko Kirin, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Regeneron, Sanofi-Aventis/Genzyme

Advisory Boards: AbbVie, Amgen, Astellas, Bausch Health/Valeant, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dow Pharma, Eli Lilly, Galderma, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Sanofi-Aventis/Genzyme, Sun Pharma, UBC

AKH Staff and Planners

Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner: has disclosed no relevant financial relationships.

Dionne Cotterman, AKH Project Coordinator: has disclosed no relevant financial relationships.

Accreditation Information

Target Audience

This activity is intended for dermatologists, physicians, and other healthcare professionals in Lebanon and Jordan.

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Kikaku America International. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Commercial Support

This activity is supported by an educational grant from Novartis Pharma Service Inc. The providers of this program have waived the processing fees.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure Declaration

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

Contact Information

Kikaku America International, please contact [email protected].

Course Viewing Requirements*

Supported Browsers:

- Internet Explorer 9.0+ for Windows 2003 and above

- Google Chrome 28.0+ for Windows, macOS, or Linux

- Mozilla Firefox 23.0+ for Windows, macOS, or Linux

- Microsoft Edge 20+ for Windows or macOS

- Safari 6.0+ for Mac OS X Lion (10.7) and above

Supported Phones & Tablets:

- Android 4.0.3 (Ice Cream Sandwich) and above

- iPhone/iPad with iOS 6.1 or above

* Most devices and browsers unlisted that are able to playback YouTube™ and/or support NPAPI (Adobe) or PPAPI (Chromium) based flash player capabilities are compatible.

Method of Participation

In order to receive credit, participants should watch the entire video. Once you have watched the video, you will continue to the online quiz and evaluation. A passing score of 70% on the quiz is required to receive credit. A statement of credit will be available upon successful completion of the quiz and evaluation. You must participate in the entire activity to receive credit. There is no fee to participate in this activity.

If you have questions about this activity, please contact AKH Inc. at [email protected].

Video Course